Series A PR

Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis Funds will be used to advance amyloid fibrils specific ClariTY technology platform as a potential best-in-class therapy for patients with Amyloidosis Download Press...

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!